Mamta K Jain

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection
    Mamta K Jain
    UT Southwestern Medical Center, Department of Internal Medicine, Dallas, TX, USA
    Antimicrob Agents Chemother 57:1115-20. 2013
  2. ncbi Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9113, USA
    AIDS Patient Care STDS 26:73-80. 2012
  3. ncbi Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000
    Mamta K Jain
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Clin Infect Dis 36:1030-8. 2003
  4. ncbi Role of ribavirin in HCV treatment response: now and in the future
    Mamta K Jain
    UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas 75390 9113, USA
    Expert Opin Pharmacother 11:673-83. 2010
  5. ncbi Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 4323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Infect Dis 200:866-76. 2009
  6. ncbi Biliary parasites: diagnostic and therapeutic strategies
    Niraj Khandelwal
    Mamta K Jain, MD, MPH Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9113, USA
    Curr Treat Options Gastroenterol 11:85-95. 2008
  7. ncbi Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors
    M K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
    HIV Med 8:491-7. 2007
  8. ncbi Drug-induced liver injury associated with HIV medications
    Mamta K Jain
    University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Clin Liver Dis 11:615-39, vii-viii. 2007
  9. ncbi Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 9113, USA
    AIDS Patient Care STDS 20:817-22. 2006
  10. ncbi Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response
    M K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Viral Hepat 14:176-82. 2007

Research Grants

  1. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2004
  2. Molecular Basis of Interferon Response in HCV
    Mamta Jain; Fiscal Year: 2007
  3. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2007

Collaborators

Detail Information

Publications21

  1. ncbi Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection
    Mamta K Jain
    UT Southwestern Medical Center, Department of Internal Medicine, Dallas, TX, USA
    Antimicrob Agents Chemother 57:1115-20. 2013
    ..Optimizing dose to patient weight and PEGIFN AUC in the first week offers a solution to improve SVR and to potentially shorten duration of therapy...
  2. ncbi Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9113, USA
    AIDS Patient Care STDS 26:73-80. 2012
    ..Further studies are needed in a prospective cohort to evaluate the predictive value of monitoring changes in fibrosis scores over time to predict mortality in patients with viral hepatitis...
  3. ncbi Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000
    Mamta K Jain
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Clin Infect Dis 36:1030-8. 2003
    ..AIDS-defining illnesses continue to be a major cause of mortality in the HAART era in populations where access to care and adherence to HAART is limited...
  4. ncbi Role of ribavirin in HCV treatment response: now and in the future
    Mamta K Jain
    UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas 75390 9113, USA
    Expert Opin Pharmacother 11:673-83. 2010
    ..Higher serum concentrations of ribavirin are associated with higher response rates but also higher rates of hemolytic anemia which is a dose limiting side effect. Alternatives to current therapy are under clinical evaluation...
  5. ncbi Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 4323 Harry Hines Boulevard, Dallas, TX 75390, USA
    J Infect Dis 200:866-76. 2009
    ..We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein...
  6. ncbi Biliary parasites: diagnostic and therapeutic strategies
    Niraj Khandelwal
    Mamta K Jain, MD, MPH Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9113, USA
    Curr Treat Options Gastroenterol 11:85-95. 2008
    ..However, oral treatment is inexpensive and effective for most of these parasites and can prevent untoward consequences. Primary and alternative treatments are available and are reviewed in this article...
  7. ncbi Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors
    M K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
    HIV Med 8:491-7. 2007
    ..We evaluated the effect of HCV on risk of DM in relation to traditional risk factors such as age, body mass index (BMI) and family history of DM in an HIV-infected population...
  8. ncbi Drug-induced liver injury associated with HIV medications
    Mamta K Jain
    University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Clin Liver Dis 11:615-39, vii-viii. 2007
    ..This article reviews the different HIV drug classes, incidence of elevated liver enzyme values by class and by individual drug, risk factors, specific toxicities, and possible mechanisms of injury...
  9. ncbi Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 9113, USA
    AIDS Patient Care STDS 20:817-22. 2006
    ..Distinguishing clearly between drug-related hepatotoxicity and hepatitis reactivation may be difficult but is important as their clinical management differs...
  10. ncbi Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response
    M K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Viral Hepat 14:176-82. 2007
    ..More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy...
  11. ncbi Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
    Mamta K Jain
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
    Clin Infect Dis 44:996-1000. 2007
    ..The common occurrence of hepatitis B virus (HBV) infection in patients who carry the human immunodeficiency virus (HIV) demands that both viruses be recognized, evaluated, and treated when appropriate...
  12. ncbi Hepatitis B virus genotype G: prevalence and impact in patients co-infected with human immunodeficiency virus
    Doan Y Dao
    Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    J Med Virol 83:1551-8. 2011
    ..Further studies are needed to understand why this genotype occurs more frequently and what impact it has on liver disease progression in patients with HBV/HIV...
  13. ncbi A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy
    HeJun Yuan
    Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX 75390 9113, USA
    J Med Virol 84:1913-9. 2012
    ....
  14. ncbi Evaluation and treatment of the patient coinfected with hepatitis B and HIV
    Ellen Kitchell
    Department of Internal Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Curr HIV/AIDS Rep 5:103-11. 2008
    ..Improved ability to obtain long-term HBV DNA suppression and avoid resistance will translate into improved survival in this population...
  15. ncbi Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection
    Adam C Yopp
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Gastroenterol Hepatol 10:1284-90. 2012
    ..We compared the clinical presentation, treatment, and survival of patients with HCC, with and without HIV infection...
  16. ncbi Host-based ribavirin resistance influences hepatitis C virus replication and treatment response
    Kristie D Ibarra
    Department of Microbiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9048, USA
    J Virol 85:7273-83. 2011
    ..Our results uncovered a novel form of antiviral drug resistance and suggest that host-based RBV resistance develops in HCV patients undergoing therapy and that maintenance of RBV uptake may contribute to rapid viral clearance...
  17. ncbi Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations
    Carol S North
    the VA North Texas Health Care System, Dallas, TX, USA
    Gen Hosp Psychiatry 35:122-8. 2013
    ..This review was undertaken to summarize recent experience in the treatment of HCV in clinical settings, examining the course of patients through the stages of treatment and barriers to treatment encountered...
  18. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  19. ncbi Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV
    Mamta K Jain
    AIDS 21:2365-6. 2007
  20. ncbi Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study
    Norbert Brau
    Bronx Veterans Affairs VA Medical Center, Infectious Disease Section 111F, 130 West Kingsbridge Road, Bronx, NY 10468, USA
    J Hepatol 47:527-37. 2007
    ..HIV-infected patients now live longer and often have complications of liver disease, especially with hepatitis B or C virus coinfection. Limited data are available on those with hepatocellular carcinoma (HCC)...
  21. ncbi Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections
    David A Kosub
    Seattle Biomedical Research Institute, 307 Westlake Ave N, Seattle, WA 98109, USA
    J Virol 82:1155-65. 2008
    ..The SIV(+) sooty mangabey natural hosts, which do not proceed to clinical AIDS, provide evidence that gammadelta T-cell dysfunction occurs in HIV(+) patients and may contribute to HIV disease progression...

Research Grants5

  1. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2004
    ..abstract_text> ..
  2. Molecular Basis of Interferon Response in HCV
    Mamta Jain; Fiscal Year: 2007
    ....
  3. U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT
    Mamta Jain; Fiscal Year: 2007
    ..abstract_text> ..